Optimizing Treatment Duration and Adverse Effect Management in Patients with NDMM
Dr. Cook and Dr. Pianko share their perspectives on optimizing treatment strategies for individual patients in order to maximize response and mitigate adverse events.
Selecting an Appropriate Frontline Treatment Regimen for Patients With Advanced RCC
Moshe Ornstein, MD, explains how he selects a frontline IO/TKI combination regimen for a patient with advanced renal cell carcinoma.
Comparing IO/TKI and IO/IO First-Line Treatment Regimens in Advanced RCC
Dr Brian Rini shares his view on the data comparing IO/TKI and IO/IO combination regimens for the treatment of advanced renal cell carcinoma.
Non-Immunotherapy Interventions May Successfully Target Renal Cell Carcinoma
A better understanding of tumor biology may be necessary for identifying novel non-immunotherapy–based therapeutic strategies for patients with renal cell carcinoma, according to Rana R. McKay, MD.
Expert Describes Direct Tumor Killing Strategies in Renal Cell Carcinoma
Probiotics and other agents targeting fatty acid oxidation are also under evaluation as treatment options for patients with renal cell carcinoma, according to Rana R. McKay, MD.
NDMM Risk-Stratification and Other Factors Informing Treatment Selection
Defining transplant eligibility, explaining the role of transplant in NDMM, and differentiating between high- and low-risk MM.
Key Trial Data Guiding Treatment Decisions for Patients with NDMM
Thoughtful discussion centered around recently presented updates to the GRIFFIN, MASTER, and GMMG-CONCEPT studies in NDMM patients.
Emerging BCMA Targeting Bispecifics in Multiple Myeloma
Panelists reflect on the evolving landscape of BCMA targeting bispecifics and how additional agents will impact the management of multiple myeloma.
Factors in Selecting Frontline Therapy for Advanced Bladder Cancer
Centering focus on the first-line treatment armamentarium, key opinion leaders consider factors that aid in the selection of best therapy for patients with advanced bladder cancer.
Best Supportive Care for Patients With Bladder Cancer
A brief discussion on supportive care available to patients with bladder cancer and the role it plays within the treatment pathway.
Supportive Care Strategies for Patients with MM on Bispecifics Treatment
Key opinion leaders consider when it is appropriate to utilize bispecific dose holds or reductions when treating patients with multiple myeloma.
Belzutifan Generates ‘Excitement’ in Renal Cell Carcinoma, Expert Says
Other angiogenic agents are also under investigation in renal cell carcinoma, according to Rana McKay, MD, who indicates it will be interesting to see how they compare with belzutifan.
Unmet Needs in the Treatment of Multiple Myeloma
The panel highlights remaining unmet needs in the management of multiple myeloma and speculates on the future of treatment.
Comparing Bispecifics and CAR T-Cell Therapy for Patients With MM
Noffar Bar, MD, shares how she would choose between the potential bispecific antibodies for treatment of multiple myeloma after recent data updates.
Trial Data and Experience With Amivantamab in EGFR Exon20+ NSCLC
Expert perspectives on clinical trial data and personal experience with amivantamab in the setting of EGFR Exon20+ non–small cell lung cancer.
First- and Second-Line Treatment Options for EGFR Exon20+ NSCLC
Key opinion leaders in non–small cell lung cancer management reflect on the current first- and second-line treatment options available to patients with EGFR Exon20+ disease.
Relapsed/Refractory CLL: Overview of the Treatment Landscape
A Matching-Adjusted Indirect Comparison of Acalabrutinib Versus Zanubrutinib in Relapsed or Refractory Chronic Lymphocytic Leukemia
Patient Monitoring after Adjuvant Chemotherapy in Colorectal Cancer
Medical oncologists who specialize in gastrointestinal cancers offer clinical insights on monitoring patients following treatment with adjuvant chemotherapy.
CAR T-Cell Therapy in Transplant-Ineligible Patients with MM
Nausheen Ahmed, MD, and Al-Ola Abdallah, MD, discuss the use of CAR T-cell therapy in patients with transplant-ineligible multiple myeloma.
Treatment Considerations for Transplant-Ineligible Patients with MM
The expert panel gives an overview of factors that influence treatment decisions in patients with transplant-ineligible multiple myeloma.
.png%3Ffit%3Dcrop%26auto%3Dformat&w=3840&q=75 "NDMM Risk-Stratification and Other Factors Informing Treatment Selection")
